Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SIGMA ALDRICH CORP.

Seegene Partners with Hamilton to Develop Random Access System

By Labmedica International staff writers
Posted on 28 Sep 2017
Print article
Image: Seegene has signed a Memorandum of Understanding (MoU) with Hamilton Company to develop the Seegene Random Access System (Photo courtesy of iStock).
Image: Seegene has signed a Memorandum of Understanding (MoU) with Hamilton Company to develop the Seegene Random Access System (Photo courtesy of iStock).
Seegene (Seoul, South Korea), a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company (Reno, NV, USA), which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.

The Seegene Random Access System is a molecular diagnostics solution that provides order-to-report on the same day by integrating simultaneous and high multiplex real-time PCR testing on Hamilton’s automated liquid handling platforms, regardless of specimen and assay type. Seegene expects the collaboration to accelerate the development of the Random Access System and to complete the Digitalized Development System, which enables the automation of whole development process from reagent development, clinical studies, manufacturing to quality control.

“To achieve the Seegene Random Access System, the integration of technologies applied in reagent, instrument and software is necessary. Through our collaboration, we will be able to accelerate the accomplishment of ‘Seegene Random Access System’,” said Dr. Jong Yoon Chun, CEO and founder of Seegene. “Molecular diagnostics testing is currently limited to large hospitals or clinical laboratories; however, with the completion of the system, molecular diagnostics utilization will greatly increase as order-to-report on the same day allows hospitals to conduct molecular diagnosis and this will lead to a breakthrough in achieving on-time customized patient care.”


Print article

Channels

Copyright © 2000-2017 Globetech Media. All rights reserved.